produits : BT-001

BT-001

BT-001 is a multifunctional oncolytic virus

encoding for an anti-CTLA4 antibody and GM-CSF

BT-001 is the first oncolytic virus from Invir.IO™ and is optimized to act as a Trojan horse.

Two specific “weapons” have been integrated into the Vaccinia viral DNA: an anti-CTLA4 antibody, which was developed by BioInvent, and the cytokine GM-CSF, which triggers the body’s immune response.

Discover how BT-001 works

Collaboration agreement

BioInvent and Transgene are together creating a novel armed oncolytic virus that will be able to infect and selectively replicate within the tumor, inducing cancer cell destruction, and to elicit a strong immune response that is further enhanced by the local expression of the immune checkpoint inhibitor and the cytokine. This novel oncolytic virus is expected to deliver better treatment outcomes with an improved safety profile as the patient is not exposed to the the anti-CTLA4 antibody at a systemic level.

Clinical trials

IndicationPhase
Solid tumorsPhase I/IIaMore information

Public Information (ENNLFR)

Transgene sa
400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166
67405 Illkirch Graffenstaden Cedex - France |
Tel. : + 33 (0) 3 88 27 91 00

 

© 2021 Transgene - All rights reserved
Terms of use - Credits